PD1-vaxx and B-vaxx: Kaumaya article in Brit ash Journal of Cancer, page-15

Have you looked? This was just in 15 minutes over my morning coffee. I think there might be a reason for Bisantrene being a 'forgotten' drug.
Sorry about the formatting.

Moderate to Life threatening leukopenia as dose limiting toxicity at 220 mg/sqm/week after two weeks in 4 out of 5 patients. Severe swelling for 6 months.

Alberts, D. S., Mackel, C., Pocelinko, R., & Salmon, S. E. (1982). Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay. Cancer research, 42(3), 1170–1175.

Anaphylactoid Reaction

300 mg/sqm (40 pts 9 PR, 18 SD)

Yap, H.-Y., Yap, B.-S.,Blumenschein, G. R., Barnes, B. C., Schell, F. C., & Bodey, G. P. (1983).Bisantrene, an Active New Drug in the Treatment of Metastatic Breast Cancer. Cancer Research, 43(3), 1402.

Anaphylactoid Reactions in 9 out of 93 patients, lifethreatening toxicity.

Myers, J. W., Von Hoff, D. D., Kuhn, J. G., Osborne, C. K.,Sandbach, J. F., & Pocelinko, R. (1983). Anaphylactoid reactions associatedwith bisantrene infusions. Investigational new drugs, 1(1),85–88.

Myelosupression.

Osborne, C. K., Von Hoff, D. D., Cowan, J. D., &Sandbach, J. (1984). Bisantrene, an active drug in patients with advancedbreast cancer. Cancer treatment reports, 68(2), 357–360.

43 adverse effects recorded amongst 10 patients. Numerousgrade 3 & 4 SAEs and one 5, including leukopenia, thrombocytopenia, cardiacinfarct and mucositis.

Canaani, J., Danylesko, I., Shemtov, N., Zlotnick, M., Lozinsky,K., Benjamini, O., Yerushalmi, R., Nagar, M., Dor, C., Shimoni, A., Avigdor,A., & Nagler, A. (2021). A phase II study of bisantrene in patients withrelapsed/refractory acute myeloid leukemia. European journal of haematology,106(2), 260–266.